The Journey of Ibuprofen

Ibuprofen is well absorbed from the gastrointestinal tract, with
oral bioavailability of approximately 80-90%. Being a weak acid (pKa 4.4), it is predominantly
un-ionized in the acidic stomach, facilitating passive absorption across the gastric and
duodenal mucosa. Peak plasma concentrations are achieved in 1-2 hours after an oral dose on an
empty stomach; food delays but does not reduce overall absorption. All marketed oral ibuprofen
is the racemic mixture of R(-) and S(+) enantiomers. The S(+)-enantiomer is the active
inhibitor of cyclooxygenase enzymes; the R(-)-enantiomer has minimal COX inhibitory activity
at baseline but undergoes metabolic chiral inversion. A liquid suspension achieves peak
concentrations somewhat faster than tablets. Topical ibuprofen (gel formulations) achieves
local tissue concentrations at the application site sufficient for anti-inflammatory effect
with minimal systemic absorption.

Ibuprofen is extensively bound to plasma proteins at 99%,
predominantly albumin, with a volume of distribution of 0.1-0.2 L/kg reflecting restricted
extravascular distribution. Despite high plasma binding, the free fraction distributes into
synovial fluid (concentrations 50-60% of plasma), peritoneal fluid, saliva, and CSF. Synovial
fluid concentrations persist longer than plasma levels because binding to joint proteins slows
exit from this compartment — a pharmacokinetic feature that may contribute to sustained
anti-inflammatory effect in arthritis beyond the apparent short plasma half-life. Ibuprofen
crosses the placenta (use contraindicated after 20 weeks gestation due to premature ductus
arteriosus closure and oligohydramnios) and is secreted into breast milk at very low
concentrations, generally considered compatible with breastfeeding.

Ibuprofen reversibly inhibits both COX-1 and COX-2 through
competitive, time-dependent binding. Unlike aspirin, ibuprofen does not acetylate the enzyme;
it occupies the substrate (arachidonic acid) channel as a structural mimic of arachidonic acid's
carboxylate group, blocking access to the catalytic tyrosine and heme iron. The S(+)-enantiomer
is 160-fold more potent than the R(-)-form against COX-1 and has substantially higher affinity
for COX-2. Inhibition of COX-1 reduces thromboxane A₂ production in platelets (antiplatelet
effect, reversible and short-lived unlike aspirin), and decreases protective prostaglandin E₂
and I₂ in the gastric mucosa (contributing to GI toxicity). COX-2 inhibition blocks prostaglandin
E₂ and I₂ in inflammatory foci, reducing vasodilation, sensitization of nociceptors, and
central pain processing — accounting for analgesic, anti-inflammatory, and antipyretic effects.

The chiral inversion of R(-)-ibuprofen to S(+)-ibuprofen
represents an unusual metabolic activation pathway. The enzyme 2-arylpropionyl-CoA epimerase
(and other members of this pathway) converts R(-)-ibuprofenyl-CoA to S(+)-ibuprofenyl-CoA,
which is then hydrolyzed to yield the pharmacologically active S(+)-enantiomer. Approximately
60% of administered R(-)-ibuprofen undergoes this inversion in humans. Additionally, both
enantiomers undergo oxidative metabolism to hydroxy- and carboxy-metabolites by CYP2C9 and
CYP2C8. These oxidized metabolites are pharmacologically inactive and subsequently conjugated
(glucuronidation by UGT enzymes). CYP2C9 polymorphisms (poor metabolizers carrying *2 or *3
alleles) can lead to 2-fold higher ibuprofen exposure.

Ibuprofen and its conjugated metabolites are excreted primarily
in urine (90%), with a small biliary/fecal component. Urinary metabolites include hydroxyibuprofen,
carboxyibuprofen, and their glucuronide conjugates. The elimination half-life of ibuprofen is
short — 1.8-2.5 hours — explaining the need for dosing every 4-8 hours for sustained anti-
inflammatory effect. The short half-life also means that antiplatelet effects are transient
and COX function fully recovers within 24 hours of stopping treatment, unlike aspirin's
irreversible antiplatelet action. In renal impairment, metabolite accumulation occurs, and
reduced prostaglandin synthesis further compromises renal hemodynamics (NSAID-induced acute
kidney injury mechanism).

Ibuprofen is one of the most widely used analgesic/anti-inflammatory
drugs globally. At OTC doses (200-400 mg), it is effective for mild-to-moderate pain and fever.
At prescription doses (up to 3200 mg/day), it has anti-inflammatory efficacy in rheumatoid
arthritis and other inflammatory conditions. Cardiovascular risk (elevated with all NSAIDs
except aspirin, attributed to COX-2-mediated reduction in prostacyclin with persisting
thromboxane), GI ulceration, and renal prostaglandin-dependent vasoconstriction are class
effects. Drug interactions include inhibition of aspirin's antiplatelet effect (by competing
for COX-1 binding site) and increased risk of lithium toxicity (reduced renal lithium clearance).